KRAS and neoplasm: A double-stranded miR-217 mimic encapsulated in a PEGylated lipid nanoparticle, decorated with iRDG tumor penetrating–peptide, is effective at downregulating KRAS expression in vitro cell assays, but it may not be as effective as short interfering RNAs (siRNAs) against KRAS in an in vivo subcutaneous PDAC tumor model [129].